摘要
目的:探讨阿托伐他汀对稳定性心绞痛患者血浆微小核糖核酸(micro RNA)-143/145表达水平的影响。方法:入选74例首次服用阿托伐他汀的稳定性心绞痛患者,随机分为两组,低剂量组(n=36)患者每天服用阿托伐他汀20 mg,中等剂量组(n=38)每天服用阿托伐他汀40 mg。留取用药前、用药1个月及12月时的静脉血样,分别检测各份血样的低密度脂蛋白胆固醇(LDL-C);将74例患者按照不同时间点的LDL-C是否达标分为达标组(LDL-C<2.60 mmol/L),不达标组(LDL-C≥2.60 mmol/L);观察各组micro RNA-143/145表达水平。结果:两组患者服用阿托伐他汀后血浆microR NA-143/145表达水平均较服用前明显升高(P<0.001);中等剂量组在用药1个月和用药12个月时血浆microR NA-143/145表达水平均高于低剂量组;阿托伐他汀治疗后两组患者LDL-C均较服用前明显下降(P<0.05),且LDL-C达标组与不达标组的microR NA-143/145表达水平差异无统计学意义(P>0.05)。结论:阿托伐他汀可上调血浆microR NA-143/145表达水平,该作用与降脂无明显关系。
Objective： To investigate the effect of atorvastatin on plasma micro RNA-143/145 expression in patients with stable angina pectoris（SAP）.Methods： A total of 74 SAP patients taken atorvastatin at first time were enrolled in this study, the patients were assigned into 2 groups by the dose of medication： Low dose group, the patients received atorvastatin 20 mg/day, n=36 and Moderate dose group, the patients received atorvastatin 40 mg/day, n=38. Plasma levels of LDL-C and microR NA-143/145 were examined before medication and at 1 month, 12 months after medication respectively. The patients were further divided into another 2 groups by plasma levels of LDL-C： Reach the standard group, plasma LDL-C2.60 mmol/L and Not reach the standard group, plasma LDL-C≥2.60 mmol/L. Plasma levels of microR NA-143/145 were measured and compared between 2 groups.Results： 1 Compared with baseline condition, plasma levels of micro RNA-143/145 were increased in both groups after medication, P0.001 the levels in Moderate dose group were higher than those in Low dose group at both 1 month and 12 months of time points. 2 Plasma levels of LDL-C were decreased with medication in both groups, P〈0.05. Micro RNA-143/145 expression was similar between Reach the standard group and Not reach the standard group, P〉0.05.Conclusion： Atorvastatin could up-regulate plasma micro RNA-143/145 expression, which was not related to lipiddecreasing effect.
出处
《中国循环杂志》
CSCD
北大核心
2014年第12期972-975,共4页
Chinese Circulation Journal
